Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712904 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03712904 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 3 participants.
The verdict
NCT03712904, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- BIOLOGICAL Ziv-Aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-09 |
| Est. Completion | 2022-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712904
The ClinicalTrials.gov registry entry for NCT03712904 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT03712904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712904 about?
NCT03712904 is a clinical study titled "Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma". This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause l...
What is the current status of trial NCT03712904?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-08-09. Estimated completion is 2022-12-23.
What interventions are being tested in trial NCT03712904?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Ziv-Aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT03712904?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.